Literature DB >> 14609031

Cardiac expression of Gal4 causes cardiomyopathy in a dose-dependent manner.

Petra E M H Habets1, Danielle E W Clout, Ronald H Lekanne Deprez, Marian A van Roon, Antoon F M Moorman, Vincent M Christoffels.   

Abstract

Cardiac expression of a transgene is a common approach for determining the role of gene products in the processes underlying cardiomyopathy and heart failure (HF). We have generated transgenic mice that express the 'harmless' yeast transcription factor Gal4 in the heart under control of the alpha-myosin heavy chain promoter and found that expression of this gene causes cardiomyopathy and HF, the severity of which correlated with the number of copies of the transgene integrated into the genome and with the expression level. A line with a single copy of the transgene targeted to the hprt locus correctly expressed the transgene but did not develop cardiomyopathy. Our results indicate that expression of a transgene in the heart may non-specifically cause HF in a dose-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14609031     DOI: 10.1023/a:1026055612227

Source DB:  PubMed          Journal:  J Muscle Res Cell Motil        ISSN: 0142-4319            Impact factor:   2.698


  21 in total

Review 1.  Meeting Koch's postulates for calcium signaling in cardiac hypertrophy.

Authors:  K R Chien
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 2.  Cardiac gap junction channels: modulation of expression and channel properties.

Authors:  A A van Veen; H V van Rijen; T Opthof
Journal:  Cardiovasc Res       Date:  2001-08-01       Impact factor: 10.787

3.  Transgenic remodeling of the regulatory myosin light chains in the mammalian heart.

Authors:  J Gulick; T E Hewett; R Klevitsky; S H Buck; R L Moss; J Robbins
Journal:  Circ Res       Date:  1997-05       Impact factor: 17.367

4.  Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice.

Authors:  A Subramaniam; W K Jones; J Gulick; S Wert; J Neumann; J Robbins
Journal:  J Biol Chem       Date:  1991-12-25       Impact factor: 5.157

5.  Occurrence and distribution of atrial natriuretic peptide-containing cells in the left ventricle of hypertensive rats. Effect of antihypertensive treatment.

Authors:  E Kaganovsky; V Belkin; Y Barhum; J Schaper; W Schaper; G Kessler-Icekson
Journal:  Cell Tissue Res       Date:  2001-01       Impact factor: 5.249

6.  Appropriate tissue- and cell-specific expression of a single copy human angiotensinogen transgene specifically targeted upstream of the HPRT locus by homologous recombination.

Authors:  B Cvetkovic; B Yang; R A Williamson; C D Sigmund
Journal:  J Biol Chem       Date:  2000-01-14       Impact factor: 5.157

7.  Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals.

Authors:  S Izumo; A M Lompré; R Matsuoka; G Koren; K Schwartz; B Nadal-Ginard; V Mahdavi
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

8.  Function of the sarcoplasmic reticulum and expression of its Ca2(+)-ATPase gene in pressure overload-induced cardiac hypertrophy in the rat.

Authors:  D de la Bastie; D Levitsky; L Rappaport; J J Mercadier; F Marotte; C Wisnewsky; V Brovkovich; K Schwartz; A M Lompré
Journal:  Circ Res       Date:  1990-02       Impact factor: 17.367

9.  Single-copy transgenic mice with chosen-site integration.

Authors:  S K Bronson; E G Plaehn; K D Kluckman; J R Hagaman; N Maeda; O Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

10.  Cellular localization and structural characterization of natriuretic peptide-expressing ventricular myocytes from patients with dilated cardiomyopathy.

Authors:  M Tanaka; M Hiroe; T Nishikawa; T Sato; F Marumo
Journal:  J Histochem Cytochem       Date:  1994-09       Impact factor: 2.479

View more
  6 in total

Review 1.  Artificial chromosome-based transgenes in the study of genome function.

Authors:  Jason D Heaney; Sarah K Bronson
Journal:  Mamm Genome       Date:  2006-08-04       Impact factor: 2.957

2.  A targeted gene expression system using the tryptophan repressor in zebrafish shows no silencing in subsequent generations.

Authors:  Arminda Suli; Ali D Guler; David W Raible; David Kimelman
Journal:  Development       Date:  2014-03       Impact factor: 6.868

Review 3.  Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy.

Authors:  Dongsheng Duan
Journal:  Hum Mol Genet       Date:  2006-10-15       Impact factor: 6.150

4.  100-fold but not 50-fold dystrophin overexpression aggravates electrocardiographic defects in the mdx model of Duchenne muscular dystrophy.

Authors:  Yongping Yue; Nalinda B Wasala; Brian Bostick; Dongsheng Duan
Journal:  Mol Ther Methods Clin Dev       Date:  2016-07-06       Impact factor: 6.698

5.  Efficient disruption of Zebrafish genes using a Gal4-containing gene trap.

Authors:  Jorune Balciuniene; Danielle Nagelberg; Kathleen T Walsh; Diana Camerota; Daphné Georlette; Frédéric Biemar; Gianfranco Bellipanni; Darius Balciunas
Journal:  BMC Genomics       Date:  2013-09-14       Impact factor: 3.969

Review 6.  A most formidable arsenal: genetic technologies for building a better mouse.

Authors:  James F Clark; Colin J Dinsmore; Philippe Soriano
Journal:  Genes Dev       Date:  2020-10-01       Impact factor: 11.361

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.